The cost effectiveness watchdog claims AstraZeneca and Daiichi-Sankyo have not offered a fair price for use in the larger HER2-low setting.
AstraZeneca’s Enhertu has been rejected for use in patients with HER2-low breast cancer in England, with the country’s cost watchdog accusing the company of failing to offer “a fair price.”
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.
Enzene's CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier's India visit, he also talks about front-loading capacity at Enzene's US plant and a change in its biosimilars strategy
Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.
Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.
Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.
A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.
